Cover Introduction ProSure Clinical Studies ... - Abbott Nutrition

More documents

Recommendations

Info

CoverIntroductionProSureClinical StudiesSupportingPublicationsAn eicosapentaenoic acid supplement versus megestrol acetate versus both for patientswith cancer-associated wasting: a North Central Cancer Treatment Group and NationalCancer Institute of Canada collaborative effortJatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gagnon B, Novotny, PJ, Mailliard JA, Bushey TIL, Nair S, Christensen BJ Clin Oncol. 2004 Jun 15;22(12):2469-2476In this prospective, randomized, double-blind, controlled trial patientswith incurable cancer and weight loss greater than 5 pounds (2.3 kg)within 2 months (or physician-estimated caloric intake < 20 kcal/kgbody weight/day) were randomly assigned to receive either an EPAcontaining nutritional supplement (ProSure) plus placebo megestrolacetate, megestrol acetate plus an isocaloric, isonitrogenous controlnutritional supplement, or an EPA containing nutritional supplementplus megestrol acetate. The primary endpoint was a 10% weight gainfrom baseline between each of the EPA groups and the megestrolacetate plus control group.ObjectiveTo determine whether an EPA-containing nutritional supplement–eitheralone or in combination with megestrol acetate (MA)–improves weight,appetite, quality of life, and survival in advanced cancer patients withcancer-associated wasting, compared with MA alone.• The megestrol acetate + control group had a greater percentageof patients with ≥ 10% weight gain (18%) compared to the EPA +megestrol acetate group (11%) and the EPA + placebo megestrolacetate group. This was statistically significant. However, whencomparing % of patients with ANY weight gain, there were nostatistically significant differences among the groups.• No difference among groups in the QoL assessment.• No difference among groups for length of survival.• A greater incidence of impotence was noted in the megestrolacetate + control group.EPA -eicosapentaenoic acidStudy Design• Study Population: Incurable malignancies, excluding brain,breast, ovarian, prostate, or endometrial cancer (n = 421; n = 141EPA + placebo megestrol acetate group, n = 140 megestrol acetate+ control group, n = 140 EPA + megestrol acetate group)• Length of Study: 4 weeks• Intervention: 2 servings/day ProSure (240 mL/serving) orisocaloric, isonitrogenous controlOutcomes• Weight gain. Both ProSure- and megestrol acetate-treated groupshad more than one-third of patients gaining weight over the 4-weekcourse. ProSure was as effective as megesterol acetate, and therewere fewer side effects with ProSure.*P = 0.004 vs EPA + placebo megestrol acetate group alone but nodifference (P = 0.17) between the two megestrol acetate groups.**statistics not providedStudy ConclusionsThe authors conclude that ProSure alone or with megestrol acetatewas no better than megestrol acetate alone.
Critical considerations on the use of a protein and energy dense omega-3 enrichedsip feed in cancer patientsCoverCapuano G, Pavese I, Satta F, Coiro G, Todi F, Zoffoli MV, Tosti M, Palladino A, Di Palma MRivista Italiana di Nutrizione Parenterale ed Enterale. 2005;23:43-46IntroductionProSureClinical StudiesSupportingPublicationsCapuano and colleagues conducted a prospective, single-arm studyin patients with cancer cachexia.ObjectiveTo determine the compliance and effects of ProSure on body massindex (BMI), body weight, ECOG performance status, prealbumin, andretinol binding protein in cancer patients.Study Design• Study Population: Ambulatory patients with a variety of cancertypes (n = 22)• Length of Study: 4 weeks• Intervention: 2 servings ProSure (240 mL/serving)Outcomes• A positive correlation was observed with supplement intake andboth weight gain, 3 kg ± 1 (range 2-4 kg) and improvement inperformance status.Study ConclusionsThe researchers concluded that patients’ adherence to therecommended dose of supplements such as ProSure is critical tothe prevention and treatment of cancer cachexia. Alterations or lossof taste, preference for foods or nutritional supplements may affectintake of supplements. Improvements in acceptability and palatabilitymay help the treatment of cancer-related weight loss.EPA -eicosapentaenoic acid
Page 1 and 2: CoverIntroductionProSureClinical St
Page 5 and 6: Fish-oil enriched nutritional suppl
Page 7 and 8: Effect of a fish-oil enriched nutri
Page 9 and 10: Effect of a protein and energy dens
Page 11 and 12: CoverReduced total energy expenditu
Page 13 and 14: EPA enriched nutritional support an
Page 15 and 16: A double blind randomized controlle
Page 19 and 20: CoverThe effect of an oral nutritio
Page 21 and 22: CoverEffect of oral supplementation
Page 23 and 24: CoverThe effect of eicosapentaenoic
Page 25 and 26: Enteral nutrition enriched with eic
Page 27 and 28: CoverComplementary effect of ProSur
Page 29 and 30: CoverNutritional support including
Page 31: Nutrition intervention improves out
Page 37 and 38: CoverDietary omega-3 polyunsaturate
Page 39 and 40: CoverNutritional intervention with
Page 41 and 42: CoverDefinition and classification

Cover Introduction ProSure Clinical Studies ... - Abbott Nutrition

Create successful ePaper yourself

Delete template?

Save as template?